+44 131 440 6541

human cells for drug discovery

Your complete solution for human iPSC based cells and services.

Roslin Cell Sciences is focused on induced pluripotent stem cell (iPSC) based research services to deliver data demonstrating human cell response to candidate drugs across a diversity of genotypes.

Our capabilities are concentrated on creating large numbers of iPSC lines from diverse cohorts of donors and the subsequent development and implementation of human stem cell derived models of disease in support of commercial and academic drug research.

Roslin Cell Sciences is a wholly owned subsidiary of Censo Biotechnologies.

10 May 2016

Roslin stem cell companies combine to create Censo Biotechnologies group.

iPSC GENERATION

iPSC GENERATION

Generating your own iPSC lines is a lengthy and labour intensive process. We offer a whole product solution for iPSC production. We are able to source donors or primary cells, generate the iPSCs and deliver them to our customers, with the characterisation, protocols and technical support they require.

We have a variety of reprogramming methods and culture conditions, as well as a large range of best practice characterisation tests to choose from.

Back to top
CELL PRODUCTS

CELL PRODUCTS

We can provide iPSC derived cell types for your research. We develop our protocols to produce our progenitor and differentiated cells with cryopreservation stages which will allow us to deliver ‘assay ready’ cells.

We can currently produce the following cell types for our clients from both our and our clients cell lines:

Other cell types in development include:

Back to top
IN-VITRO ASSAYS

IN-VITRO ASSAYS

Within Roslin Cell Sciences we believe that the utilisation of novel phenotypically relevant human cell systems is critical to better understanding of disease processes, the identification of small chemical entities which would positively impact these disease processes or indeed to stratify existing medicines for specific patient genotypes.

Utilising control and disease iPSC lines a number of assays are currently being developed in house which are tailored to deliver disease specific screening cascades. These consist of robust primary assays to create initial compound leads and can be followed by disease relevant secondary and tertiary phenotypic assays to explore structure activity relationships if appropriate.

We take a collaborative approach to engaging with our customers to develop iPSC-based in-vitro assay platforms for their drug discovery research.

Back to top
You are using an outdated browser. Please click here to upgrade.